Last 28 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -11.61 | 40.11 | — | — | — | — | — | 58.11 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.34 | 3.61 | 2.74 | 3.28 | 5.53 | 6.41 | 7.99 | 7.97 | 13.90 | 10.84 | 27.15 | 34.44 | 31.79 | 41.25 | 54.82 | 71.83 | 58.52 | 177.91 | 33.93 | 43.81 | 107.55 |
| — | -43.6% | -65.7% | -58.9% | -60.2% | -40.9% | -70.6% | -76.8% | -56.3% | -73.7% | -50.5% | -52.1% | -45.7% | -76.8% | +61.6% | +64.0% | -45.6% | +160.8% | -49.8% | +93.7% | +31.4% | |
| P/B Ratio | 3.42 | 4.55 | 3.45 | 4.01 | 5.95 | 6.31 | 6.13 | 5.72 | 7.98 | 6.98 | 8.77 | 8.75 | 9.11 | 8.60 | 12.20 | 10.67 | 8.60 | 15.14 | 12.79 | 8.92 | 32.45 |
| — | -27.9% | -43.6% | -29.9% | -25.4% | -9.6% | -30.1% | -34.6% | -12.5% | -18.8% | -28.1% | -18.0% | +5.9% | -43.2% | -4.6% | +19.6% | -73.5% | -9.5% | -31.7% | +43.1% | +166.4% | |
| P/FCF | — | — | — | — | 63.26 | — | — | — | — | — | 275.23 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 21.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 22.54 | — | — | — | — | — | 32.93 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.3% | 64.5% | 42.3% | 59.7% | 57.7% | 61.6% | 63.4% | 60.4% | 65.4% | 73.0% | 41.8% | 59.2% | 49.3% | -75.2% | 2.0% | -2.1% | -375.0% | -41.5% | -96.8% | 100.0% | 100.0% |
| — | +4.8% | -33.2% | -1.1% | -11.8% | -15.6% | +51.9% | +2.0% | +32.5% | +197.0% | +1998.8% | +2918.8% | +113.2% | -81.2% | +102.1% | -102.1% | -475.0% | -141.5% | +75.6% | 0.0% | 0.0% | |
| Operating Margin | -13.3% | 14.9% | -16.3% | -6.7% | -16.0% | -8.6% | -26.0% | -39.9% | -43.7% | -22.5% | -125.4% | -150.8% | -96.4% | -272.9% | -340.2% | -465.4% | -910.9% | -996.4% | -375.8% | -300.6% | -508.4% |
| — | +273.6% | +37.1% | +83.1% | +63.5% | +61.9% | +79.3% | +73.6% | +54.6% | +91.8% | +63.1% | +67.6% | +89.4% | +72.6% | +9.5% | -54.8% | -79.2% | -134.2% | +64.2% | -109.6% | +4.8% | |
| Net Margin | -28.8% | 8.6% | -17.8% | -10.1% | -14.6% | -49.2% | -51.7% | 14.1% | -78.2% | -9.8% | -63.6% | -182.2% | -64.8% | -271.6% | -308.5% | -491.7% | -310.5% | -1614.1% | -99.4% | -226.5% | -736.0% |
| — | +117.4% | +65.6% | -171.4% | +81.4% | -403.9% | +18.7% | +107.7% | -20.7% | +96.4% | +79.4% | +62.9% | +79.1% | +83.2% | -210.4% | -117.1% | +57.8% | -267.2% | +82.4% | -61.4% | -37.8% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -29.1% | 3.0% | -5.5% | -3.1% | -3.9% | -12.2% | -9.8% | 2.4% | -11.0% | -1.6% | -5.0% | -11.2% | -4.5% | -19.3% | -16.0% | -18.3% | -13.0% | -38.6% | -6.8% | -17.8% | -44.3% |
| — | +124.7% | +43.8% | -225.6% | +64.8% | -679.6% | -98.1% | +121.8% | -143.2% | +91.9% | +69.1% | +38.8% | +65.2% | +49.9% | -135.2% | -2.5% | +70.7% | -15.1% | +66.1% | -43.6% | -145.1% | |
| ROA | -17.4% | 2.0% | -3.3% | -1.8% | -2.3% | -7.6% | -6.1% | 1.5% | -7.1% | -1.0% | -3.3% | -7.9% | -3.3% | -12.7% | -8.8% | -10.2% | -7.2% | -18.7% | -3.8% | -9.1% | -14.8% |
| — | +126.1% | +46.9% | -215.9% | +67.1% | -644.9% | -86.1% | +119.7% | -114.9% | +92.0% | +62.6% | +23.1% | +54.3% | +32.3% | -132.0% | -11.7% | +51.4% | -52.4% | +68.6% | -13.0% | -65.3% | |
| ROIC | -12.7% | 5.6% | -6.1% | -1.9% | -2.8% | -1.6% | -3.7% | -5.3% | -4.6% | -3.3% | -19.6% | -18.0% | -11.7% | -37.5% | -33.7% | -95.9% | -111.0% | -31.5% | -59.7% | -109.2% | — |
| — | +457.6% | -64.1% | +64.8% | +38.0% | +52.8% | +81.0% | +70.6% | +60.9% | +91.2% | +41.9% | +81.2% | +89.5% | -19.2% | +43.6% | +12.1% | — | — | — | +57.0% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.41 | 0.23 | 0.40 | 0.41 | 0.41 | 0.37 | 0.36 | 0.34 | 0.31 | 0.29 | 0.29 | 0.26 | 0.24 | 0.23 | 0.48 | 0.38 | — | 0.35 | 0.29 | 0.16 | 0.33 |
| — | -39.6% | +12.9% | +22.5% | +30.6% | +28.1% | +24.0% | +28.3% | +29.8% | +29.1% | -40.3% | -31.3% | — | -34.9% | +63.5% | +138.1% | — | +488.0% | +1841.6% | +2493.6% | +2633.5% | |
| Debt / EBITDA | — | 4.63 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.96 | 3.04 | 2.13 | 1.96 | 2.86 | 4.71 | 5.20 | 4.62 | 4.98 | 4.84 | 5.66 | 6.92 | 8.61 | 8.01 | 3.84 | 3.69 | 3.69 | 3.22 | 3.83 | 4.14 | 2.37 |
| — | -35.4% | -59.1% | -57.6% | -42.5% | -2.8% | -8.2% | -33.2% | -42.1% | -39.6% | +47.3% | +87.5% | +133.3% | +148.9% | +0.5% | -10.9% | +55.6% | +16.6% | +17.5% | -19.4% | -51.4% | |
| Quick Ratio | 1.91 | 2.94 | 2.05 | 1.91 | 2.80 | 4.57 | 5.07 | 4.54 | 4.90 | 4.78 | 5.57 | 6.83 | 8.51 | 7.93 | 3.79 | 3.66 | 3.66 | 3.19 | 3.81 | 4.14 | 2.37 |
| — | -35.8% | -59.5% | -57.9% | -42.9% | -4.3% | -9.1% | -33.6% | -42.4% | -39.8% | +47.0% | +86.8% | +132.7% | +149.0% | -0.5% | -11.6% | +54.5% | +15.7% | +17.6% | -19.3% | -51.4% | |
| Interest Coverage | -12.21 | 288.50 | -8.65 | -2.58 | -6.92 | -22.82 | -18.59 | 8.86 | -20.96 | -2.28 | -9.92 | -24.23 | -10.01 | -20.12 | -20.90 | -26.92 | -44.55 | -116.51 | -70.86 | -145.73 | -419.25 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LEGN stock.
Legend Biotech Corporation's current P/E is -11.6x. The average P/E over the last 1 quarters is 40.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Legend Biotech Corporation's current operating margin is -13.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Legend Biotech Corporation's business trajectory between earnings reports.